Review: A review of the use of zonisamide in Parkinson’s disease

Although zonisamide was previously only used to treat epilepsy, recently more applications have been forthcoming. Due to a good side effect profile, a lower frequency of interactions and a more comfortable posology, there are several studies regarding its uses in other pathologies such as migraine,...

Full description

Bibliographic Details
Main Authors: Pedro Emilio Bermejo, Buenaventura Anciones
Format: Article
Language:English
Published: SAGE Publishing 2009-09-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/1756285609338501
id doaj-0fcdf18af2b74eca994952ca242c2d34
record_format Article
spelling doaj-0fcdf18af2b74eca994952ca242c2d342020-11-25T02:52:41ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28562009-09-01210.1177/1756285609338501Review: A review of the use of zonisamide in Parkinson’s diseasePedro Emilio BermejoBuenaventura AncionesAlthough zonisamide was previously only used to treat epilepsy, recently more applications have been forthcoming. Due to a good side effect profile, a lower frequency of interactions and a more comfortable posology, there are several studies regarding its uses in other pathologies such as migraine, neuropathic pain, essential tremor and various psychiatric diseases. A multicentered, randomized, double-blind, placebo-controlled study conducted in Japan suggested that zonisamide, as an add-on treatment, has efficacy in treating motor symptoms in patients with Parkinson’s disease. In addition, other studies support the utility of zonisamide in other symptoms of this disease. The therapeutic doses of zonisamide for the treatment of Parkinson’s disease are considerably lower than those for the treatment of epilepsy. This antiepileptic drug has been used in Japan for more than 15 years and so it is expected that it will be safe and well tolerated in patients with Parkinson’s disease. However, the pharmacological mechanisms of the antiparkinsonian actions of zonisamide remain unclear and more basic investigation is warranted. The aim of this paper is to review the structure, mechanisms of action, pharmacokinetics and antiparkinsonian action of zonisamide.https://doi.org/10.1177/1756285609338501
collection DOAJ
language English
format Article
sources DOAJ
author Pedro Emilio Bermejo
Buenaventura Anciones
spellingShingle Pedro Emilio Bermejo
Buenaventura Anciones
Review: A review of the use of zonisamide in Parkinson’s disease
Therapeutic Advances in Neurological Disorders
author_facet Pedro Emilio Bermejo
Buenaventura Anciones
author_sort Pedro Emilio Bermejo
title Review: A review of the use of zonisamide in Parkinson’s disease
title_short Review: A review of the use of zonisamide in Parkinson’s disease
title_full Review: A review of the use of zonisamide in Parkinson’s disease
title_fullStr Review: A review of the use of zonisamide in Parkinson’s disease
title_full_unstemmed Review: A review of the use of zonisamide in Parkinson’s disease
title_sort review: a review of the use of zonisamide in parkinson’s disease
publisher SAGE Publishing
series Therapeutic Advances in Neurological Disorders
issn 1756-2856
publishDate 2009-09-01
description Although zonisamide was previously only used to treat epilepsy, recently more applications have been forthcoming. Due to a good side effect profile, a lower frequency of interactions and a more comfortable posology, there are several studies regarding its uses in other pathologies such as migraine, neuropathic pain, essential tremor and various psychiatric diseases. A multicentered, randomized, double-blind, placebo-controlled study conducted in Japan suggested that zonisamide, as an add-on treatment, has efficacy in treating motor symptoms in patients with Parkinson’s disease. In addition, other studies support the utility of zonisamide in other symptoms of this disease. The therapeutic doses of zonisamide for the treatment of Parkinson’s disease are considerably lower than those for the treatment of epilepsy. This antiepileptic drug has been used in Japan for more than 15 years and so it is expected that it will be safe and well tolerated in patients with Parkinson’s disease. However, the pharmacological mechanisms of the antiparkinsonian actions of zonisamide remain unclear and more basic investigation is warranted. The aim of this paper is to review the structure, mechanisms of action, pharmacokinetics and antiparkinsonian action of zonisamide.
url https://doi.org/10.1177/1756285609338501
work_keys_str_mv AT pedroemiliobermejo reviewareviewoftheuseofzonisamideinparkinsonsdisease
AT buenaventuraanciones reviewareviewoftheuseofzonisamideinparkinsonsdisease
_version_ 1724728261639929856